Weight loss pills Novo Nordisk weight loss pills
Novo Nordisk weight loss pills 10 tablets
Competition for GLP-1 drugs intensifies: Who will dominate the market?
Novo Nordisk's Wegovy and Ozempic are competing fiercely with rival Eli Lilly's popular weight loss drug Zepbound and diabetes drug Mounjaro.
Wegovy and its main ingredient, diabetes treatment Ozempic, and Mounjaro, are all GLP-1 receptor agonists, which help control blood sugar, slow digestion and reduce hunger, allowing people who take them to eat less. This will become the focus of competition in the Indian and global markets in the future.
The companies have been struggling to meet surging demand in the United States and the few countries that have launched the drugs. In a race to dominate the weight-loss market, both Novo Nordisk and Eli Lilly are accelerating production expansions, but supply remains insufficient.
Analysts predict that the global weight loss market is expected to reach US$150 billion per year in the next 10 years.
Nordisk received regulatory approval for injectable semaglutide, the active ingredient in Wegovy and Ozempic, in India in late 2022. While the company is working to accelerate the launch of Wegovy, it has not yet set a launch date.
On the other hand, Eli Lilly said its plan to launch Mounjaro in 2025 also depends on supply conditions.
Last month, Novo Nordisk launched Wegovy in China, the world's second-largest drug market, hoping to capture the market among China's huge obese population. The drug is priced at about 1,400 yuan (about 193.27 U.S. dollars) for a monthly starting dose, which is much lower than the price in the United States (about 1,349 U.S. dollars per month).
Meishi weight loss pills
Weight loss pills recommended
US Stock Weight Loss Drugs
Musk weight loss pills
Japanese weight loss pills
Diabetes weight loss pills
American slimming pills slimming pills ptt
Wu Zongxian slimming pills slimming pills principle Novo Nordisk slimming pills slimming pills Eli Lilly
